Moderna is trading up 4.89% at $231.63 on November 3, 2026, with no confirmed company-specific catalyst identified.
- Reports about its cancer-vaccine data and November 6 earnings provide background but do not confirm a reason for the gain.
- Biotech is down 2.39%, while major indices are mixed; neither clearly explains Moderna’s rise. The immediate driver remains uncertain.